AcuraStem - About the company
AcuraStem is a seed company based in Monrovia (United States), founded in 2016 by Justin Ichida, Paul August, Sam Alworth and Qing Liu. It operates as a Developer of therapeutics for neurodegenerative diseases. AcuraStem has raised $780K in funding. The company has 494 active competitors, including 167 funded and 96 that have exited. Its top competitors include companies like Alector, Passage Bio and Juvenescence.
Company Details
Developer of therapeutics for neurodegenerative diseases. The company has an iNeuroRx technology platform to advance highly promising therapeutic candidates for the treatment of Amyotrophic Lateral Sclerosis and frontotemporal dementia. It offers a lead candidate AS 1 which is a small molecule therapeutic targeting Amyotrophic Lateral Sclerosis.
- Website
- acurastem.com
- Social
- Email ID
- *****@acurastem.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2016
Location
Monrovia, United States
Stage
Seed
Total Funding
$780K in 10 rounds
Latest Funding Round
Investors
Ranked
88th among 494 active competitors
Employee Count
32 as on Mar 31, 2026
Sign up to download AcuraStem's company profile
AcuraStem's funding and investors
AcuraStem has raised a total funding of $780K over 10 rounds. Its first funding round was on Sep 15, 2017. Its latest funding round was a Grant (prize money) round on Feb 12, 2025 for $*****. 1 investor participated in its latest round. AcuraStem has 6 institutional investors.
Here is the list of recent funding rounds of AcuraStem:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Feb 12, 2025 | 4344261 | Grant (prize money) | 5219353 | 4798149 | 5276252 | 6521522 |
Jan 30, 2024 | 9111146 | Grant (prize money) | 3229882 | 8132307 | 4885591 | |
Aug 01, 2023 | 1920824 | Grant (prize money) | 8134756 | 3394949 | 6753129 |
Access funding benchmarks and valuations. Sign up today!View details of AcuraStem's funding rounds and investors
AcuraStem's founders and board of directors
Founder? Claim ProfileHere are the details of AcuraStem's key team members:
- Justin Ichida: Co-Founder of AcuraStem.
- Paul August: Former Co-Founder of AcuraStem. Contact Info: 1 email address
- Sam Alworth: Co-Founder & CEO of AcuraStem. Contact Info: 1 email address
- Qing Liu: Co-Founder of AcuraStem.
View details of AcuraStem's Founder profiles and Board Members
AcuraStem's employee count trend
AcuraStem has 32 employees as of Mar 26. Here is AcuraStem's employee count trend over the years:
Uncover AcuraStem's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
AcuraStem's Competitors and alternates
Top competitors of AcuraStem include Alector, Passage Bio and Juvenescence. Here is the list of Top 10 competitors of AcuraStem, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | 73/100 | |
2nd | _1560516450043.png?devicePixelRatio=2&height=30&width=30){kind=logo} Passage Bio 2017, Philadelphia (United States), Public | Developer of gene therapies for CNS rare diseases | $226M | 69/100 | |
3rd |  Juvenescence 2017, Dublin (Ireland), Series B | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | $290M | 68/100 | |
4th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 67/100 | |
5th | Harmony Biosciences 2017, Plymouth Meeting (United States), Public | Developer of therapeutics for rare neurological diseases | $345M | 66/100 | |
6th | MeiraGTx 2015, New York City (United States), Public | Developer of gene therapies for ocular and neurodegenerative diseases | - | 65/100 | |
7th |  Mammoth 2017, Brisbane (United States), Series D | Provider of molecular diagnostics platform by using CRISPR technology | $271M | 65/100 | |
8th | Axsome Therapeutics 2012, New York City (United States), Public | Developer of therapeutic solutions for the management of CNS disorders | $8.7M | 65/100 | |
9th | Evox Therapeutics 2016, Oxford (United Kingdom), Series C | Developer of exosome-based therapies for neurological diseases | $156M | 64/100 | |
10th | Mission Therapeutics 2011, Cambridge (United Kingdom), Series D | Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response | $192M | 63/100 | |
88th |  AcuraStem 2016, Monrovia (United States), Seed | Developer of therapeutics for neurodegenerative diseases | $780K | 50/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on AcuraStem's competitors? Click here to see the top ones
AcuraStem's Investments and acquisitions
AcuraStem has made no investments or acquisitions yet.
News related to AcuraStem
Media has covered AcuraStem for 1 event in last 1 year, It was about company updates.
•
•
•
•
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about AcuraStem
Explore our recently published companies
- Dancepoint - Unfunded company
- Farmairinc - 2017 founded, Unfunded company
- Beachfeet - 2003 founded, Unfunded company
- Tedsports - 2001 founded, Unfunded company
- Sensibleshoe - 2005 founded, Unfunded company
- Korkers - 1959 founded, Unfunded company
